ADOCIA Shares Surge 26.46% Over the Week, Boosted by Analyst Recommendation
The Lyon-based company specializing in diabetes and obesity treatments experienced a particularly dynamic week, closing at €9.75 on Friday, October 10. This weekly increase of 26.46% is in stark contrast to the downturns of the CAC 40 and SBF 120, which both fell by approximately 1.7% over the same period.
The week was marked by a significant acceleration on Thursday, October 9, where the stock jumped 35.40% to reach €10.48, before slightly retracting to €9.75 the following day. Trading volumes skyrocketed on this occasion, with more than 2 million shares traded on Thursday, approximately 11% of the company's capital, compared to less than 300,000 shares in previous sessions. This surge is part of a particularly robust medium-term dynamic, with the stock showing a growth of 148.7% over three months and 81.56% over a year, a considerable gap compared to the Parisian indices which have increased by about 4.6% over twelve months. On Friday, despite a 7% decline from the previous day's high, volumes remained strong with 1.36 million shares traded, indicating sustained investor interest.
Sharp Rise Following Analyst Coverage
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
This sharp rise followed the initiation of coverage by Invest Securities on Thursday, October 9, with the analysis firm setting a buy recommendation and a price target of €17.90. This target price represents an upside potential of over 80% compared to the closing price on Friday, which largely explains the surge in trading volumes observed. Analysts justify their position by the significant potential of the company in the drug delivery technology segment applied to diabetes and obesity, a rapidly expanding market. The peak reached on Thursday at €10.48 now constitutes a technical resistance level to watch, while the support identified at €7.30 remains relatively distant, offering a comfortable margin in case of consolidation.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 2T2026
Key reported figures
Revenue: 43K€
Guidance from the release
« Au cours de ce trimestre, nous avons continué d’avancer, avec notre partenaire Tonghua Dongbao, vers le dépôt de la demande d’autorisation de mise sur le marché en Chine de BioChaperone® Lispro. »
Le chiffre d'affaires du trimestre, limité à 43 K€, provient d'une étude de faisabilité sur la technologie BioChaperone® pour un partenaire non divulgué. La trésorerie s'établit à 9,7 M€ au 30 juin 2026 contre 17,2 M€ fin 2025. La Société recentre ses priorités sur BioChaperone®, met en pause M1Pram après l'expiration du droit exclusif de négociation de Sanofi et suspend la demande d'essai clinique d'AdoShell®.
Risks mentioned
Horizon de trésorerie limité au début du deuxième trimestre 2027
Trésorerie en baisse à 9,7 M€ au 30 juin 2026 contre 17,2 M€ fin 2025
Expiration du droit exclusif de négociation de Sanofi sur M1Pram et mise en pause du programme
Suspension de la demande d'essai clinique AdoShell® faute de ressources financières et humaines
Opportunities identified
Dépôt en préparation de la demande d'AMM en Chine de BioChaperone® Lispro par Tonghua Dongbao
Paiement d'étape de 20 millions de dollars US conditionné à l'AMM chinoise, plus redevances à deux chiffres
Discussions de prochaines étapes engagées avec deux grandes sociétés pharmaceutiques sur BioChaperone®
Nouvelle plateforme brevetée AdoXLong™ visant une injection mensuelle, protection potentielle jusqu'en 2046
Bons de souscription pouvant générer jusqu'à 10,2 et 11,5 millions d'euros en cas de hausse du cours
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
